Mirjana Kessler

Head of the Research Lab

LMU Klinikum

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Cancer Biology Cancer Biology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mirjana Kessler is the Head of the Research Lab at LMU Klinikum in Germany. Her research focuses on oncogenes in ovarian and endometrial cancers, as well as the epigenetic changes related to reproductive health. Recent publications include studies on patient-derived ovarian cancer organoids and their implications for personalized medicine. She also explores molecular markers and prognostic factors related to breast cancer and oocyte aging.

Articles (11)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (4)

Vincent Cavaillès

University of Montpellier

FRANCE

View details

Jalid Sehouli

GERMANY

View details

Pedro Rodriguez Cutillas

Professor of Cell Signalling & Proteomics

Barts Cancer Institute

UNITED KINGDOM

View details

Stefanie Corradini

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mirjana Kessler

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Expression of Intracellular Galectin-8 and -9 in Endometrial Cancer

Establishment of Stable Knockdown of MACC1 Oncogene in Patient-Derived Ovarian Cancer Organoids

In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients

Cytoplasmic Localization of Thyroid Hormone Receptor (TR) Alpha and Nuclear Expression of Its Isoform TRα2 Determine Survival in Breast Cancer in Opposite Ways

Protocol to optimize the biobanking of ovarian cancer organoids by accommodating patient-specific differences in stemness potential

Cytoplasmic Colocalization of RXRα and PPARγ as an Independent Negative Prognosticator for Breast Cancer Patients

Cytoplasmic Colocalization of RXR alpha and PPAR gamma as an Independent Negative Prognosticator for Breast Cancer Patients

Epigenetic changes occur in placentas of spontaneous and recurrent miscarriages

Epigenetic changes occur in placentas of spontaneous and recurrent miscarriages

FAM111A Is a Novel Molecular Marker for Oocyte Aging

FAM111A Is a Novel Molecular Marker for Oocyte Aging

Collaborators (4)

Vincent Cavaillès

Jalid Sehouli

Pedro Rodriguez Cutillas

Stefanie Corradini

Make your next move.

Mirjana Kessler

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Expression of Intracellular Galectin-8 and -9 in Endometrial Cancer

Establishment of Stable Knockdown of MACC1 Oncogene in Patient-Derived Ovarian Cancer Organoids

In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients

Cytoplasmic Localization of Thyroid Hormone Receptor (TR) Alpha and Nuclear Expression of Its Isoform TRα2 Determine Survival in Breast Cancer in Opposite Ways

Protocol to optimize the biobanking of ovarian cancer organoids by accommodating patient-specific differences in stemness potential

Cytoplasmic Colocalization of RXR&alpha; and PPAR&gamma; as an Independent Negative Prognosticator for Breast Cancer Patients

Cytoplasmic Colocalization of RXR alpha and PPAR gamma as an Independent Negative Prognosticator for Breast Cancer Patients

Epigenetic changes occur in placentas of spontaneous and recurrent miscarriages

Epigenetic changes occur in placentas of spontaneous and recurrent miscarriages

FAM111A Is a Novel Molecular Marker for Oocyte Aging

FAM111A Is a Novel Molecular Marker for Oocyte Aging

Collaborators (4)

Vincent Cavaillès

Jalid Sehouli

Pedro Rodriguez Cutillas

Stefanie Corradini

Make your next move.

Cytoplasmic Colocalization of RXRα and PPARγ as an Independent Negative Prognosticator for Breast Cancer Patients